Australian pharmaceutical company LTR Pharma has begun recruiting subjects in a bioequivalence clinical study of SPONTAN, a quick-acting nasal spray designed to treat erectile dysfunction (ED).

LTR Pharma Limited (AU:LTP) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - ...

FDA reported that, for now, companies can continue to market OTC monograph drug products containing oral phenylephrine as a ...

Neffy, a new epinephrine nasal spray, offers a less invasive option for treating allergic reactions. Learn about its benefits ...

Researchers at Tel Aviv University have developed an effective, inexpensive, and simple COVID-19 vaccine that can be stored ...

Semax, a synthetic analogue of the adrenocorticotropic hormone (ACTH), has been extensively researched for its neuroprotective and neuroregenerative properties. Developed in the late 1980s by Russian ...

An impaired driving criminal case sparked the researcher's curiosity over whether nasal sprays can have the same intoxicating ...

A future treatment for Alzheimer disease may involve a nasal spray. Researchers at Università Cattolica and Fondazione ...

The APS enables registered medical practitioners to prescribe Spontan to a broader class of patients with ED, streamlining ... Aptar Pharma's expertise in nasal spray technology.